Safety and Immunogenicity of H1/IC31®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm3: A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial.

Reither, K; Katsoulis, L; Beattie, T; Gardiner, N; Lenz, N; Said, K; Mfinanga, E; Pohl, C; Fielding, KL; Jeffery, H; +10 more... Kagina, BM; Hughes, EJ; Scriba, TJ; Hanekom, WA; Hoff, ST; Bang, P; Kromann, I; Daubenberger, C; Andersen, P; Churchyard, GJ; (2014) Safety and Immunogenicity of H1/IC31®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm3: A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial. PloS one, 9 (12). e114602. ISSN 1932-6203 DOI: https://doi.org/10.1371/journal.pone.0114602

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1371/journal.pone.0114602

Abstract

Share

Download

Filename: pone.0114602.pdf

Licence: Creative Commons: Attribution 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar